Integral Molecular Celebrates 25th Anniversary

PHILADELPHIA, Nov. 12, 2026 /CourierPR/ -- Integral Molecular, a founding member of Philadelphia's biotechnology community, celebrates its 25th anniversary by bringing together its expertise in antibody discovery, protein engineering, and specificity testing to build a broad pipeline of therapeutic antibodies for cancer and other diseases. The company, which was founded in 2001 by Drs. Benjamin Doranz, has since evolved from developing specialized technologies and services to building its own therapeutic antibody pipeline. Integral Molecular has been advancing the drug discovery process by unlocking the potential of difficult-to-treat diseases, such as cancer, through its subsidiary Cell Surface Bio, which has generated antibodies against challenging membrane proteins where others have been unsuccessful.

The company has made significant strides in advancing antibody drug discovery and development, particularly against targets that have long been out of reach. Integral Molecular has leveraged its combination of several core technologies, including antibody discovery, lead optimization, and specificity testing, to achieve these advancements. The company's antibody discovery capabilities have allowed it to unlock access to difficult membrane proteins, which have historically been challenging to target. This has opened new avenues for drug discovery against hard-to-treat diseases.

Integral Molecular's lead optimization technology, Paratope-PLUS®, combines CDR-Scanning technology with AI-assisted antibody engineering to identify antibody variants with improved properties. This has enabled the development of better therapeutics and the creation of new intellectual property. The company's specificity testing technology, the Membrane Proteome Array (MPA), identifies unintended off-target antibody binding to human proteins, helping the industry develop safer therapeutic candidates and avoid clinical failure. The MPA also supports regulatory submissions, ensuring that the therapeutic candidates meet the necessary standards for approval.

Integral Molecular has been pursuing over 100 disease-associated membrane proteins that have been notoriously difficult to target. These include proteins implicated in some of the hardest-to-treat diseases, such as cancer and autoimmune disorders. The company's technologies support more than 600 biotechnology and pharmaceutical organizations worldwide, enabling them to advance their own therapeutic antibody pipelines. Integral Molecular has also been recognized as an Employer of Choice by the City of Philadelphia and a Top Workplace by The Philadelphia Inquirer, further highlighting the company's commitment to its community.

The company's achievements have not gone unnoticed. Integral Molecular's therapeutic antibody, CTIM-76, has been out-licensed and is now in clinical testing for solid tumors. The company's continued success is rooted in its community partnerships, including collaborations with the Wistar Institute, Drexel University, and the Science Center's FirstHand program. These partnerships have provided Integral Molecular with the resources and expertise necessary to continue its innovative work in the field of antibody drug discovery and development.

Integral Molecular remains committed to advancing the science of antibody drug discovery and development, with a focus on unlocking the next generation of drug targets. The company's expertise and technologies have already made significant contributions to the field, and its continued growth and success are expected to have a positive impact on the biotechnology community and beyond.